Coeliac Disease Trial, Recruiting NCT05468580 Sponsor: Medisch Spectrum Twente Condition: Coeliac Disease
Back to Coeliac Disease

Coeliac Disease Trial, Recruiting

NCT05468580
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with Median Arcuate Ligament Syndrome (MALS) after being reviewed by a specialist team (including a vascular surgeon, stomach/gut doctor, and imaging specialist) at one of two Dutch expert centres.
  • You experience pain after eating, plus at least two of the following: changing what you eat to avoid pain, losing weight without trying, or having unexplained diarrhoea.
  • Scans have shown a significant narrowing (70% or more) of a specific artery (the celiac artery) caused by a ligament pressing on it, confirmed by at least two different types of imaging, including a specific breathing-in and breathing-out CT scan.
  • An abdominal ultrasound has not found other common conditions that could explain your symptoms.
  • A camera examination of your stomach and upper small intestine showed no abnormalities, unless any changes found are related to reduced blood flow to the gut lining.

Who may not be able to join:

  • You are not a suitable candidate for the keyhole (endoscopic) procedure to release the ligament — for example, because you have had previous surgery in that area of the body.
  • You are pregnant.
  • You have previously had a procedure (surgical or via a tube/wire through a blood vessel) on the arteries supplying your digestive organs.
  • You have a significant narrowing in either of the other two main arteries that supply blood to your intestines (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: RH Geelkerken, MD PHD, Medisch Spectrum Twente

Phone: +31 534872000

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Medisch Spectrum Twente
Registry
ClinicalTrials.gov
Start date
1 April 2023
Est. completion
1 April 2027

Where this trial is recruiting

🇳🇱 Netherlands

Primary endpoints

The number of patients with significant reduction in abdominal symptoms on a VAS scale; The number of patients with significant reduction in abdominal symptoms.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov